Abstract
This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety. Only randomized controlled trials (RCTs) comparing XELOX versus FOLFOX were included. A total of 4,363 patients from eight RCTs were available for analysis. Pooled analysis revealed that there were no statistical differences between both arms in OS, and ORR. XELOX arm had a higher incidence of thrombocytopenia, hand-foot syndrome, and diarrhea, whereas neutropenia had a higher incidence in the FOLFOX group. For mCRC, the effect of XELOX is similar to FOLFOX.
Keywords:
Capecitabine; Colorectal cancer; Fluorouracil; Oxaliplatin.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Capecitabine
-
Chi-Square Distribution
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / mortality
-
Colorectal Neoplasms / pathology
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Disease Progression
-
Disease-Free Survival
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Humans
-
Leucovorin / administration & dosage
-
Neoplasm Metastasis
-
Odds Ratio
-
Organoplatinum Compounds / administration & dosage
-
Oxaloacetates
-
Risk Factors
-
Survival Analysis
-
Time Factors
-
Treatment Outcome
Substances
-
Organoplatinum Compounds
-
Oxaloacetates
-
Deoxycytidine
-
Capecitabine
-
Leucovorin
-
Fluorouracil